Implications of genetic polymorphisms in drug transporters for pharmacotherapy

Cancer Letters

Volumn 234, Issue 1, 2006, Pages 4-33

  Kerb, Reinhold ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

ABC transporter; ABCB1; Efflux; Expression; Function; Haplotype analysis; MDR1; MRP; OAT; OATP; OCT; P glycoprotein; Pgp; Pharmacodynamics; Pharmacokinetics; Single nucleotide polymorphism (SNP); SLC transporter; Uptake

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC AGENT; CEFAZOLIN; CEFOPERAZONE; DAUNORUBICIN; DIGITOXIN; DIGOXIN; DOMPERIDONE; DOXORUBICIN; ERYTHROMYCIN; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; LEVOFLOXACIN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PROPAFENONE; PROTEINASE INHIBITOR; STEROID; TAMOXIFEN; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; EPITHELIUM CELL; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; KIDNEY; LIVER; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33644781452     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.051     Document Type: Review

References (194)

1. W. Kalow, L. Endrenyi, and B. Tang Repeat administration of drugs as a means to assess the genetic component in pharmacological variability Pharmacology 58 1999 281 284
2. U.A. Meyer Pharmacogenetics - five decades of therapeutic lessons from genetic diversity Nat. Rev. Genet. 5 2004 669 676
3. R. Weinshilboum Inheritance and drug response N. Engl. J. Med. 348 2003 529 537
4. W.E. Evans, and H.L. McLeod Pharmacogenomics - drug disposition, drug targets, and side effects N. Engl. J. Med. 348 2003 538 549
5. V. Fischer, H.J. Einolf, and D. Cohen Efflux transporters and their clinical relevance Mini. Rev. Med. Chem. 5 2005 183 195
6. T. Gerloff Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution Naunyn. Schmiedebergs Arch. Pharmacol. 369 2004 69 77
7. R.B. Kim Transporters and xenobiotic disposition Toxicology 181-182 2002 291 297
8. R. Kerb, S. Hoffmeyer, and U. Brinkmann ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2 Pharmacogenomics 2 2001 51 64
9. D.M. Roden, and A.L. George Jr. The genetic basis of variability in drug responses Nat. Rev. Drug Discov. 1 2002 37 44
10. A. Ayrton, and P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469 497
11. K.I. Inui, S. Masuda, and H. Saito Cellular and molecular aspects of drug transport in the kidney Kidney Int. 58 2000 944 958
12. M.J. Dresser, M.K. Leabman, and K.M. Giacomini Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters J. Pharm. Sci. 90 2001 397 421
13. P. Borst, and R.O. Elferink Mammalian ABC transporters in health and disease Annu. Rev. Biochem. 71 2002 537 592
14. A. Bodo, E. Bakos, F. Szeri, A. Varadi, and B. Sarkadi The role of multidrug transporters in drug availability, metabolism and toxicity Toxicol. Lett. 140-141 2003 133 143
15. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322 342
16. P. Chandra, and K.L. Brouwer The complexities of hepatic drug transport: current knowledge and emerging concepts Pharm. Res. 21 2004 719 735
17. M.A. Hediger, M.F. Romero, J.B. Peng, A. Rolfs, H. Takanaga, and E.A. Bruford The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction Pflugers Arch. 447 2004 465 468
18. J.W. Jonker, and A.H. Schinkel Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3) J. Pharmacol. Exp. Ther. 308 2004 2 9
19. H. Koepsell Polyspecific organic cation transporters: their functions and interactions with drugs Trends Pharmacol. Sci. 25 2004 375 381
20. H. Miyazaki, T. Sekine, and H. Endou The multispecific organic anion transporter family: properties and pharmacological significance Trends Pharmacol. Sci. 25 2004 654 662
21. G. You The role of organic ion transporters in drug disposition: an update Curr. Drug Metab. 5 2004 55 62
22. R.G. Tirona, and R.B. Kim Pharmacogenomics of organic anion-transporting polypeptides (OATP) Adv. Drug Deliv. Rev. 54 2002 1343 1352
23. C. Pauli-Magnus, and P.J. Meier Pharmacogenetics of hepatocellular transporters Pharmacogenetics 13 2003 189 198
24. I. Ieiri, H. Takane, and K. Otsubo The MDR1 (ABCB1) gene polymorphism and its clinical implications Clin. Pharmacokinet. 43 2004 553 576
25. T. Ishikawa, Y. Onishi, H. Hirano, K. Oosumi, M. Nagakura, and S. Tarui Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1) Biol. Pharm. Bull. 27 2004 939 948
26. C. Marzolini, R.G. Tirona, and R.B. Kim Pharmacogenomics of the OATP and OAT families Pharmacogenomics 5 2004 273 282
27. T. Sakaeda, T. Nakamura, and K. Okumura Pharmacogenetics of drug transporters and its impact on the pharmacotherapy Curr. Top. Med. Chem. 4 2004 1385 1398
28. E.L. Woodahl, and R.J. Ho The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function Curr. Drug Metab. 5 2004 11 19
29. C.G. Dietrich, A. Geier, and R.P. Oude Elferink ABC of oral bioavailability: transporters as gatekeepers in the gut Gut 52 2003 1788 1795
30. A.H. Schinkel P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv. Drug Deliv. Rev. 36 1999 179 194
31. C.L. Graff, and G.M. Pollack Drug transport at the blood-brain barrier and the choroid plexus Curr. Drug Metab. 5 2004 95 108
32. M.R. Syme, J.W. Paxton, and J.A. Keelan Drug transfer and metabolism by the human placenta Clin. Pharmacokinet. 43 2004 487 514
33. M.T. Huisman, J.W. Smit, K.M. Crommentuyn, N. Zelcer, H.R. Wiltshire, and J.H. Beijnen Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs AIDS 16 2002 2295 2301
34. E.R. Meaden, P.G. Hoggard, P. Newton, J.F. Tjia, D. Aldam, and D. Cornforth P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals J. Antimicrob. Chemother. 50 2002 583 588
35. A.J. Sadeque, C. Wandel, H. He, S. Shah, and A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin. Pharmacol. Ther. 68 2000 231 237
36. B. Greiner, M. Eichelbaum, P. Fritz, H.P. Kreichgauer, O. von Richter, and J. Zundler The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J. Clin. Invest. 104 1999 147 153
37. A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) Clin. Pharmacol. Ther. 66 1999 338 345
38. L. Becquemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, and P. Jaillon Effect of grapefruit juice on digoxin pharmacokinetics in humans Clin. Pharmacol. Ther. 70 2001 311 316
39. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, and D.W. Nebert Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
40. S. Saito, A. Iida, A. Sekine, C. Ogawa, S. Kawauchi, and S. Higuchi Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population J. Hum. Genet. 47 2002 576 584
41. S. Saito, A. Iida, A. Sekine, Y. Miura, C. Ogawa, and S. Kawauchi Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR) J. Hum. Genet. 47 2002 147 171
42. S. Saito, A. Iida, A. Sekine, Y. Miura, C. Ogawa, and S. Kawauchi Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population J. Hum. Genet. 47 2002 38 50
43. A. Iida, S. Saito, A. Sekine, C. Mishima, K. Kondo, and Y. Kitamura Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins J. Hum. Genet. 46 2001 668 683
44. T. Ishikawa, A. Tsuji, K. Inui, Y. Sai, N. Anzai, and M. Wada The genetic polymorphism of drug transporters: functional analysis approaches Pharmacogenomics 5 2004 67 99
45. T. Ishikawa, H. Hirano, Y. Onishi, A. Sakurai, and S. Tarui Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses Drug Metab. Pharmacokinet. 19 2004 1 14
46. S. Conrad, H.M. Kauffmann, K. Ito, R.G. Deeley, S.P. Cole, and D. Schrenk Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution J. Hum. Genet. 46 2001 656 663
47. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, and U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin. Pharmacol. Ther. 70 2001 189 199
48. R.G. Tirona, B.F. Leake, G. Merino, and R.B. Kim Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J. Biol. Chem. 276 2001 35669 35675
49. R. Kerb, U. Brinkmann, N. Chatskaia, D. Gorbunov, V. Gorboulev, and E. Mornhinweg Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences Pharmacogenetics 12 2002 591 595
50. C. Michalski, Y. Cui, A.T. Nies, A.K. Nuessler, P. Neuhaus, and U.M. Zanger A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter J. Biol. Chem. 277 2002 43058 43063
51. T. Nozawa, M. Nakajima, I. Tamai, K. Noda, J. Nezu, and Y. Sai Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis J. Pharmacol. Exp. Ther. 302 2002 804 813
52. D.L. Kroetz, C. Pauli-Magnus, L.M. Hodges, C.C. Huang, M. Kawamoto, and S.J. Johns Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene Pharmacogenetics 13 2003 481 494
53. N. Morita, T. Yasumori, and K. Nakayama Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities Biochem. Pharmacol. 65 2003 1843 1852
54. A. Takeuchi, H. Motohashi, M. Okuda, and K. Inui Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1 Drug Metab. Pharmacokinet. 18 2003 409 412
55. M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, and Y. Sugiyama Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C) Pharmacogenetics 14 2004 749 757
56. Y. Kawasaki, Y. Kato, Y. Sai, and A. Tsuji Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population J. Pharm. Sci. 93 2004 2920 2926
57. T. Sakata, N. Anzai, H.J. Shin, R. Noshiro, T. Hirata, and H. Yokoyama Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions Biochem. Biophys. Res. Commun. 313 2004 789 793
58. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, and A. Johne Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc. Natl Acad. Sci. USA 97 2000 3473 3478
59. M. Hitzl, S. Drescher, H. van der Kuip, E. Schaffeler, J. Fischer, and M. Schwab The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 2001 293 298
60. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, and Y. Kanamori Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J. Pharmacol. Exp. Ther. 297 2001 1137 1143
61. S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, and U. Brinkmann MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine Br. J. Clin. Pharmacol. 53 2002 526 534
62. Y. Moriya, T. Nakamura, M. Horinouchi, T. Sakaeda, T. Tamura, and N. Aoyama Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects Biol. Pharm. Bull. 25 2002 1356 1359
63. T. Nakamura, T. Sakaeda, M. Horinouchi, T. Tamura, N. Aoyama, and T. Shirakawa Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects Clin. Pharmacol. Ther. 71 2002 297 303
64. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, and B. Sperker The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol Clin. Pharmacol. Ther. 72 2002 572 583
65. M. Goto, S. Masuda, H. Saito, S. Uemoto, T. Kiuchi, and K. Tanaka C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation Pharmacogenetics 12 2002 451 457
66. K. Oselin, I. Nowakowski-Gashaw, P.M. Mrozikiewicz, D. Wolbergs, R. Pahkla, and I. Roots Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene Eur. J. Clin. Invest. 33 2003 261 267
67. M. Hitzl, E. Schaeffeler, B. Hocher, T. Slowinski, H. Halle, and M. Eichelbaum Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1) Pharmacogenetics 14 2004 309 318
68. T. Lang, M. Hitzl, O. Burk, E. Mornhinweg, A. Keil, and R. Kerb Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver Pharmacogenetics 14 2004 155 164
69. D. Kobayashi, I. Ieiri, T. Hirota, H. Takane, S. Maegawa, and J. Kigawa Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta Drug Metab. Dispos. 33 2005 94 101
70. R.T. Calado, R.P. Falcao, A.B. Garcia, S.M. Gabellini, M.A. Zago, and R.F. Franco Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells Haematologica 87 2002 564 568
71. K. Oselin, T. Gerloff, P.M. Mrozikiewicz, R. Pahkla, and I. Roots MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes Fundam. Clin. Pharmacol. 17 2003 463 469
72. Y. Morita, T. Sakaeda, M. Horinouchi, T. Nakamura, K. Kuroda, and I. Miki MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects Pharm. Res. 20 2003 552 556
73. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, and T. Hirota Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin. Pharmacol. Ther. 73 2003 554 565
74. J. Mwinyi, A. Johne, S. Bauer, I. Roots, and T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin. Pharmacol. Ther. 75 2004 415 421
75. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, and C. Kyrklund High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
76. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, and J.P. Chave Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study Lancet 359 2002 30 36
77. T. Illmer, U.S. Schuler, C. Thiede, U.I. Schwarz, R.B. Kim, and S. Gotthard MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients Cancer Res. 62 2002 4955 4962
78. T. Asano, K.A. Takahashi, M. Fujioka, S. Inoue, M. Okamoto, and N. Sugioka ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation Pharmacogenetics 13 2003 675 682
79. Z.L. Brumme, W.W. Dong, K.J. Chan, R.S. Hogg, J.S. Montaner, and M.V. O'Shaughnessy Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response AIDS 17 2003 201 208
80. A. Siddiqui, R. Kerb, M.E. Weale, U. Brinkmann, A. Smith, and D.B. Goldstein Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N. Engl. J. Med. 348 2003 1442 1448
81. K. Kajinami, M.E. Brousseau, J.M. Ordovas, and E.J. Schaefer Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am. J. Cardiol. 93 2004 1046 1050
82. R. Tachibana-Iimori, Y. Tabara, H. Kusuhara, K. Kohara, R. Kawamoto, and J. Nakura Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors Drug Metab. Pharmacokinet. 19 2004 375 380
83. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and J. Lamba The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients Hum. Immunol. 63 2002 765 770
84. D. Zhu, H. Taguchi-Nakamura, M. Goto, T. Odawara, T. Nakamura, and H. Yamada Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy Antivir. Ther. 9 2004 929 935
85. I.A. Hauser, E. Schaeffeler, S. Gauer, E.H. Scheuermann, B. Wegner, and J. Gossmann ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporin-related nephrotoxicity after renal transplantation J. Am. Soc. Nephrol. 16 2005 16
86. A. Saitoh, K.K. Singh, C.A. Powell, T. Fenton, C.V. Fletcher, and R. Brundage An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children AIDS 19 2005 371 380
87. R. Winzer, P. Langmann, M. Zilly, F. Tollmann, J. Schubert, and H. Klinker No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients Ann. Clin. Microbiol. Antimicro. 4 2005 3
88. D.R. Bell, J.M. Trent, H.F. Willard, J.R. Riordan, and V. Ling Chromosomal location of human P-glycoprotein gene sequences Cancer Genet. Cytogenet. 25 1987 141 148
89. N. Kioka, J. Tsubota, Y. Kakehi, T. Komano, M.M. Gottesman, and I. Pastan P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly 185 with an altered pattern of multidrug resistance Biochem. Biophys. Res. Commun. 162 1989 224 231
90. L.A. Mickley, J.S. Lee, Z. Weng, Z. Zhan, M. Alvarez, and W. Wilson Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors Blood 91 1998 1749 1756
91. S. Ito, I. Ieiri, M. Tanabe, A. Suzuki, S. Higuchi, and K. Otsubo Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects Pharmacogenetics 11 2001 175 184
92. M. Lindell, M.O. Karlsson, H. Lennernas, L. Pahlman, and M.A. Lang Variable expression of CYP and Pgp genes in the human small intestine Eur. J. Clin. Invest. 33 2003 493 499
93. P.M. Chaudhary, E.B. Mechetner, and I.B. Roninson Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes Blood 80 1992 2735 2739
94. M.F. Fromm Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol. Sci. 25 2004 423 429
95. O. von Richter, O. Burk, M.F. Fromm, K.P. Thon, M. Eichelbaum, and K.T. Kivisto Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin. Pharmacol. Ther. 75 2004 172 183
96. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, and C. Meisel Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin. Pharmacol. Ther. 72 2002 584 594
97. C. Verstuyft, M. Schwab, E. Schaeffeler, R. Kerb, U. Brinkmann, and P. Jaillon Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur. J. Clin. Pharmacol. 58 2003 809 812
98. C. Verstuyft, S. Strabach, H. El-Morabet, R. Kerb, U. Brinkmann, and L. Dubert Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition Clin. Pharmacol. Ther. 73 2003 51 60
99. Y. Kurata, I. Ieiri, M. Kimura, T. Morita, S. Irie, and A. Urae Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein Clin. Pharmacol. Ther. 72 2002 209 219
100. T. Sakaeda, T. Nakamura, M. Horinouchi, M. Kakumoto, N. Ohmoto, and T. Sakai MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects Pharm. Res. 18 2001 1400 1404
101. M. Horinouchi, T. Sakaeda, T. Nakamura, Y. Morita, T. Tamura, and N. Aoyama Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin Pharm. Res. 19 2002 1581 1585
102. T. Gerloff, M. Schaefer, A. Johne, K. Oselin, C. Meisel, I. Cascorbi, and I. Roots MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males Br. J. Clin. Pharmacol. 54 2002 610 616
103. B.C. Goh, S.C. Lee, L.Z. Wang, L. Fan, J.Y. Guo, and J. Lamba Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J. Clin. Oncol. 20 2002 3683 3690
104. S.Y. Yi, K.S. Hong, H.S. Lim, J.Y. Chung, D.S. Oh, and J.R. Kim A variant 2677A allele of the MDR1 gene affects fexofenadine disposition Clin. Pharmacol. Ther. 76 2004 418 427
105. S.M. Sisodiya, W.R. Lin, B.N. Harding, M.V. Squier, and M. Thom Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy Brain 125 2002 22 31
106. G.J. Sills, R. Mohanraj, E. Butler, S. McCrindle, L. Collier, and E.A. Wilson Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment Epilepsia 46 2005 643 647
107. N.C. Tan, S.E. Heron, I.E. Scheffer, J.T. Pelekanos, J.M. McMahon, and D.F. Vears Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy Neurology 63 2004 1090 1092
108. C. Wandel, R. Kim, M. Wood, and A. Wood Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein Anesthesiology 96 2002 913 920
109. D.K. Yu The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J. Clin. Pharmacol. 39 1999 1203 1211
110. I. Mai, E. Stormer, M. Goldammer, A. Johne, H. Kruger, and K. Budde MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporin in renal transplant patients J. Clin. Pharmacol. 43 2003 1101 1107
111. J.P. Ioannidis, E.E. Ntzani, T.A. Trikalinos, and D.G. Contopoulos-loannidis Replication validity of genetic association studies Nat. Genet. 29 2001 306 309
112. L.R. Cardon, and L.J. Palmer Population stratification and spurious allelic association Lancet 361 2003 598 604
113. G.A. Kullak-Ublick ABC transporter regulation by bile acids: where PXR meets FXR J. Hepatol. 39 2003 628 630
114. R.G. Tirona, B.F. Leake, A.W. Wolkoff, and R.B. Kim Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J. Pharmacol. Exp. Ther. 304 2003 223 228
115. E. Hustert, A. Zibat, E. Presecan-Siedel, R. Eiselt, R. Mueller, and C. Fuss Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4 Drug Metab. Dispos. 29 2001 1454 1459
116. S. Koyano, K. Kurose, Y. Saito, S. Ozawa, R. Hasegawa, and K. Komamura Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region Drug Metab. Dispos. 32 2004 149 154
117. J. Zhang, P. Kuehl, E.D. Green, J.W. Touchman, P.B. Watkins, and A. Daly The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants Pharmacogenetics 11 2001 555 572
118. K. Tang, S.M. Ngoi, P.C. Gwee, J.M. Chua, E.J. Lee, and S.S. Chong Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations Pharmacogenetics 12 2002 437 450
119. N. Soranzo, G.L. Cavalleri, M.E. Weale, N.W. Wood, C. Depondt, and R. Marguerie Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene Genome Res. 14 2004 1333 1344
120. T. Furuno, M.T. Landi, M. Ceroni, N. Caporaso, I. Bernucci, and G. Nappi Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to parkinson's disease Pharmacogenetics 12 2002 529 534
121. B. Chowbay, S. Cumaraswamy, Y.B. Cheung, Q. Zhou, and E.J. Lee Genetic polymorphisms in MDR1 and CYP3A4 genes in asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients Pharmacogenetics 13 2003 89 95
122. K. Sai, N. Kaniwa, M. Itoda, Y. Saito, R. Hasegawa, and K. Komamura Haplotype analysis of ABCB1/MDR1 blocks in a japanese population reveals genotype-dependent renal clearance of irinotecan Pharmacogenetics 13 2003 741 757
123. S. Ozawa, A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, and S. Koyano Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 Drug Metab. Pharmacokinet. 19 2004 83 95
124. M. Sugie, E. Asakura, Y.L. Zhao, S. Torita, M. Nadai, and K. Baba Possible involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin Antimicrob. Agents Chemother. 48 2004 809 814
125. G.L. Scheffer, M. Kool, M. Heijn, M. de Haas, A.C. Pijnenborg, and J. Wijnholds Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies Cancer Res. 60 2000 5269 5277
126. R.O. Elferink, and A.K. Groen Genetic defects in hepatobiliary transport Biochim. Biophys. Acta 1586 2002 129 145
127. M. Itoda, Y. Saito, A. Soyama, M. Saeki, N. Murayama, and S. Ishida Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28 Drug Metab. Dispos. 30 2002 363 364
128. H. Wang, B. Hao, K. Zhou, X. Chen, S. Wu, and G. Zhou Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies Ann. Hum. Genet. 68 2004 563 573
129. P. Dazert, K. Meissner, S. Vogelgesang, B. Heydrich, L. Eckel, and M. Bohm Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart Am. J. Pathol. 163 2003 1567 1577
130. M. Hirouchi, H. Suzuki, M. Itoda, S. Ozawa, J. Sawada, and I. Ieiri Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2 Pharm. Res. 21 2004 742 748
131. Y.M. Lee, Y. Cui, J. Konig, A. Risch, B. Jager, and P. Drings Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3) Pharmacogenetics 14 2004 213 223
132. V. Keitel, A.T. Nies, M. Brom, J. Hummel-Eisenbeiss, H. Spring, and D. Keppler A common dubin-johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2) Am. J. Physiol. Gastrointest. Liver Physiol. 284 2003 G165 G174
133. J.S. Hulot, E. Villard, A. Maguy, V. Morel, L. Mir, and I. Tostivint A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination Pharmacogenet. Genomics 15 2005 277 285
134. H. Suzuki, and Y. Sugiyama Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition Adv. Drug Deliv. Rev. 54 2002 1311 1331
135. I. Machida, S. Wakusawa, F. Sanae, H. Hayashi, A. Kusakabe, and H. Ninomiya Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan J. Gastroenterol. 40 2005 366 370
136. G. Kullak-Ublick, R. Kerb, B. Müllhaupt, E. Renner, A. Penger, U. Brinkman, et al., A novel R432T mutation in the bile salt export pump gene (BSEP; ABCB11) is associated with recurrent hitrahepatic cholestasis in an adolescent patient, Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Dallas: Abstract: 41266, 2001.
137. M.K. Leabman, C.C. Huang, D. Stryke, S.J. Johns, M. Kawamoto, and T.E. Ferrin PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2) Pharmacol. Rev. 55 2003 399
138. H. Fukushima-Uesaka, K. Maekawa, S. Ozawa, K. Komamura, K. Ueno, and M. Shibakawa Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2) Drug Metab. Pharmacokinet. 19 2004 239 244
139. Y. Shu, M.K. Leabman, B. Feng, L.M. Mangravite, C.C. Huang, and D. Stryke PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1 Pharmacol. Rev. 56 2004 161
140. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, and W.P. Yang A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J. Biol. Chem. 274 1999 37161 37168
141. R. Ho, Y. Wang, B. Leake, and R. Kim Multiple OATP transporters mediate the cellular uptake of rosuvastatin Clin. Pharmacol. Ther. 77 2005 P64 (P11-51)
142. M. Cvetkovic, B. Leake, M.F. Fromm, G.R. Wilkinson, and R.B. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab. Dispos. 27 1999 866 871
143. G.A. Kullak-Ublick, M.G. Ismair, B. Stieger, L. Landmann, R. Huber, and F. Pizzagalli Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver Gastroenterology 120 2001 525 533
144. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa, and K. Chiba A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy Drug Metab. Pharmacokinet. 19 2004 453 455
145. K. Letschert, D. Keppler, and J. Konig Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8) Pharmacogenetics 14 2004 441 452
146. W. Lee, H. Glaeser, L.H. Smith, R.L. Roberts, G.W. Moeckel, and G. Gervasini Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry J. Biol. Chem. 280 2005 9610 9617
147. Y. Shu, M.K. Leabman, B. Feng, L.M. Mangravite, C.C. Huang, and D. Stryke Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 Proc. Natl Acad. Sci. USA 100 2003 5902 5907
148. M.K. Leabman, C.C. Huang, M. Kawamoto, S.J. Johns, D. Stryke, and T.E. Ferrin Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function Pharmacogenetics 12 2002 395 405
149. T. Sekine, S.H. Cha, and H. Endou The multispecific organic anion transporter (OAT) family Pflugers Arch. 440 2000 337 350
150. T. Fujita, C. Brown, E.J. Carlson, T. Taylor, M. de la Cruz, and S.J. Johns Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1) Pharmacogenet. Genomics 15 2005 201 209
151. J.W. Jonker, E. Wagenaar, C.A. Mol, M. Buitelaar, H. Koepsell, and J.W. Smit Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene Mol. Cell. Biol. 21 2001 5471 5477
152. G.K. Dresser, J.D. Spence, and D.G. Bailey Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin. Pharmacokinet. 38 2000 41 57
153. L. Zhang, W. Gorset, C.B. Washington, T.F. Blaschke, D.L. Kroetz, and K.M. Giacomini Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system Drug Metab. Dispos. 28 2000 329 334
154. J.E. van Montfoort, M. Muller, G.M. Groothuis, D.K. Meijer, H. Koepsell, and P.J. Meier Comparison of 'type I' and 'type II' organic cation transport by organic cation transporters and organic anion-transporting polypeptides J. Pharmacol. Exp. Ther. 298 2001 110 115
155. D.R. Umbenhauer, G.R. Lankas, T.R. Pippert, L.D. Wise, M.E. Cartwright, and S.J. Hall Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism Toxicol. Appl. Pharmacol. 146 1997 88 94
156. K.L. Mealey, S.A. Bentjen, J.M. Gay, and G.H. Cantor Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene Pharmacogenetics 11 2001 727 733
157. C. Pauli-Magnus, and D.L. Kroetz Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1) Pharm. Res. 21 2004 904 913
158. M. Siegsmund, U. Brinkmann, E. Schaffeler, G. Weirich, M. Schwab, and M. Eichelbaum Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors J. Am. Soc. Nephrol. 13 2002 1847 1854
159. E.L. Woodahl, Z. Yang, T. Bui, D.D. Shen, and R.J. Ho Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein J. Pharmacol. Exp. Ther. 310 2004 1199 1207
160. C. Balram, A. Sharma, C. Sivathasan, and E.J. Lee Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates Br. J. Clin. Pharmacol. 56 2003 78 83
161. D.I. Min, and V.L. Ellingrod C3435T mutation in exon 26 of the human MDR1 gene and cyclosporin pharmacokinetics in healthy subjects Ther. Drug Monit. 24 2002 400 404
162. C.R. Yates, W. Zhang, P. Song, S. Li, A.O. Gaber, and M. Kotb The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporin oral disposition in renal transplant patients J. Clin. Pharmacol. 43 2003 555 564
163. N. von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V.W. Armstrong No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted Cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients Clin. Chem. 47 2001 1048 1052
164. D.A. Hesselink, R.H. van Schaik, I.P. van der Heiden, M. van der Werf, P.J. Gregoor, and J. Lindemans Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporin and tacrolimus Clin. Pharmacol. Ther. 74 2003 245 254
165. V. Haufroid, M. Mourad, V. Van Kerckhove, J. Wawrzyniak, M. De Meyer, and D.C. Eddour The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporin and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 2004 147 154
166. R.H. Mathijssen, S. Marsh, M.O. Karlsson, R. Xie, S.D. Baker, and J. Verweij Irinotecan pathway genotype analysis to predict pharmacokinetics Clin. Cancer Res. 9 2003 3246 3253
167. C. Skarke, M. Jarrar, H. Schmidt, G. Kauert, M. Langer, and G. Geisslinger Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers Pharmacogenetics 13 2003 651 660
168. C. Pauli-Magnus, J. Feiner, C. Brett, E. Lin, and D.L. Kroetz No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects Clin. Pharmacol. Ther. 74 2003 487 498
169. R. Kerb, A.S. Aynacioglu, J. Brockmoller, R. Schlagenhaufer, S. Bauer, and T. Szekeres The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels Pharmacogenomics J. 1 2001 204 210
170. M. Wong, S. Evans, L.P. Rivory, J.M. Hoskins, G.J. Mann, and D. Farlow Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer Clin. Pharmacol. Ther. 77 2005 33 42
171. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and P. Bowman Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am. J. Transplant. 3 2003 477 483
172. I.A. Macphee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, and A. Johnston Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate dose requirement Transplantation 74 2002 1486 1489
173. D. Anglicheau, C. Verstuyft, P. Laurent-Puig, L. Becquemont, M.H. Schlageter, and B. Cassinat Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients J. Am. Soc. Nephrol. 14 2003 1889 1896
174. M. Goto, S. Masuda, T. Kiuchi, Y. Ogura, F. Oike, and M. Okuda CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 2004 471 478
175. I.A. MacPhee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, and A. Johnston The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am. J. Transplant. 4 2004 914 919
176. N. Tsuchiya, S. Satoh, H. Tada, Z. Li, C. Ohyama, and K. Sato Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 1182 1187
177. S.L. Plasschaert, E. Groninger, M. Boezen, I. Kema, E.G. de Vries, and D. Uges Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia Clin. Pharmacol. Ther. 76 2004 220 229
178. H.X. Zheng, S.A. Webber, A. Zeevi, E. Schuetz, J. Zhang, and J. Lamba The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis Pediatr. Transplant. 8 2004 551 557
179. A. Yamauchi, I. Ieiri, Y. Kataoka, M. Tanabe, T. Nishizaki, and R. Oishi Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene Transplantation 74 2002 571 572
180. D. Anglicheau, E. Thervet, I. Etienne, B. Hurault De Ligny, Y. Le Meur, and G. Touchard CYP3A5 and MDR1 genetic polymorphisms and cyclosporin pharmacokinetics after renal transplantation Clin. Pharmacol. Ther. 75 2004 422 433
181. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms Drug Metab. Dispos. 33 2005 434 439
182. S. Conrad, H.M. Kauffmann, K. Ito, E.M. Leslie, R.G. Deeley, D. Schrenk, and S.P. Cole A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance Pharmacogenetics 12 2002 321 330
183. L. Bonhomme-Faivre, A. Devocelle, F. Saliba, S. Chatled, J. Maccario, R. Farinotti, and V. Picard MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients Transplantation 78 2004 21 25
184. D.A. Hesselink, T. van Gelder, R.H. van Schaik, A.H. Balk, I.P. van der Heiden, and T. van Dam Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes Clin. Pharmacol. Ther. 76 2004 545 556
185. F. Puisset, E. Chatelut, F. Dalenc, F. Busi, T. Cresteil, and J. Azema Dexamethasone as a probe for docetaxel clearance Cancer Chemother. Pharmacol. 54 2004 265 272
186. R.H. Mathijssen, F.A. de Jong, R.H. van Schaik, E.R. Lepper, L.E. Friberg, and T. Rietveld Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes J. Natl Cancer Inst. 96 2004 1585 1592
187. C.B. Eap, J. Fellay, T. Buclin, G. Bleiber, K.P. Golay, and M. Brocard CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene Pharmacogenetics 14 2004 255 260
188. S. Colombo, N. Soranzo, M. Rotger, R. Sprenger, G. Bleiber, and H. Furrer Swiss HIV cohort study. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo Pharmacogenet. Genomics 15 2005 599 608
189. H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, and B.P. Griffith Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism J. Clin. Pharmacol. 44 2004 135 140
190. I. Mai, E.S. Perloff, S. Bauer, M. Goldammer, A. Johne, and G. Filler MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients Br. J. Clin. Pharmacol. 58 2004 548 553
191. M. Nasi, V. Borghi, M. Pinti, C. Bellodi, E. Lugli, and S. Maffei MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients AIDS 17 2003 1696 1698
192. C. Verstuyft, F. Marcellin, L. Morand-Joubert, O. Launay, K. Brendel, and F. Mentre Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy AIDS 19 2005 2127 2131
193. D.W. Haas, L.M. Smeaton, R.W. Shafer, G.K. Robbins, G.D. Morse, and L. Labbe Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study J. Infect. Dis. 192 2005 1931 1942
194. R.L. Roberts, P.R. Joyce, R.T. Mulder, E.J. Begg, and M.A. Kennedy A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression Pharmacogenomics J. 2 2002 191 196